Could a common drug make radiation deadlier to lung tumors?
NCT ID NCT03824327
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding a drug called papaverine to precise, high-dose radiation (SBRT) can help control non-small cell lung cancer. About 19 patients with a single lung tumor will receive both treatments. The main goal is to find the safest dose and see if the combination improves tumor control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Papaverine hydrochloride (a drug that may make cancer cells more sensitive to radiation)
What this could lead to
If it works, this could point toward a way to make radiation therapy more effective for lung cancer, potentially improving tumor control.
What could go wrong
This is a very early (Phase I) trial with only 19 participants, so it is primarily testing safety and dosing. It may not show a clear benefit, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States